ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1360

Functional Consequences of NOD2 Gene Variants in Patients with NOD2-Associated Autoinflammatory Disease

Christine McDonald1, Min Shen1, Amrita Kabi1, Craig Homer1 and Qingping Yao2, 1Cleveland Clinic, Cleveland, OH, 2Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Autoinflammatory Disease, Biomarkers, cytokines, innate immunity and nod-like receptor (NLR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Innate Immunity and Rheumatic Disease Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Yao Syndrome (YS) is a systemic autoinflammatory disease formerly termed Nucleotide-binding oligomerization domain 2 (NOD2)-associated AutoInflammatory Disease (NAID) due to its association with specific genetic variants in NOD2. This study examined the function of NOD2 in YS patients.

Methods:

Study subjects (10 YS patients and 5 healthy individuals) were screened for NOD2 variants by sequencing or TaqMan probes. Plasma cytokine levels, NOD2 expression, and transcript splicing were measured by ELISA, qRT-PCR, and PCR, respectively. Functional assays were performed with peripheral blood mononuclear cells to assess NOD2activation in response to its ligand, muramyl dipeptide. The efficacy of tocilizumab therapy was examined in a YS patient.

Results: All YS patients were heterozygous for the NOD2 IVS8+158 variant and 4 were compound heterozygous for R702W. Plasma levels of TNFα, IL-1β, IFNγ, and S100A12 were unaltered in YS patients as compared to healthy individuals. Splicing of intron 8 was unaffected by carriage of the IVS8+158 variant; however, NOD2 expression was elevated in IVS8+158 heterozygous patients but not in IVS8+158/R702W compound heterozygotes. MDP-stimulated NFκB activity was suppressed uniquely in compound heterozygotes and correlated with lower TNFα secretion. IL-6 secretion was enhanced specifically in IVS8+158 heterozygotes and anti-IL6 receptor antibody (tocilizumab) treatment of a YS patient with this NOD2 genotype resulted in significant clinical improvement.

Conclusion:

Our findings indicate that YS is associated with dysfunction of NOD2, and specific NOD2 genotypes associate with distinct functional subtypes. This study suggests that NOD2 genotype could be used as a biomarker in the selection of therapeutic modalities for YS and warrants further investigation in clinical trials.


Disclosure: C. McDonald, None; M. Shen, None; A. Kabi, None; C. Homer, None; Q. Yao, None.

To cite this abstract in AMA style:

McDonald C, Shen M, Kabi A, Homer C, Yao Q. Functional Consequences of NOD2 Gene Variants in Patients with NOD2-Associated Autoinflammatory Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/functional-consequences-of-nod2-gene-variants-in-patients-with-nod2-associated-autoinflammatory-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/functional-consequences-of-nod2-gene-variants-in-patients-with-nod2-associated-autoinflammatory-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology